{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-018234","form_type":"8-K","ticker":"QNRX","cik":"0001671502","company_name":"Quoin Pharmaceuticals, Ltd.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.385548+00:00","generated_at":"2026-05-26T02:12:56.784118+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Quoin Pharma: pediatric Netherton Syndrome patient shows dramatic skin healing after 2 weeks of QRX003","bullets":["IGA score improved from 7 to 1-2 (0-10 scale) after two weeks of whole-body QRX003 treatment.","Pruritus (itch) score reduced from 5 to 1; patient stopped all antihistamines, glucocorticoids, and antivirals.","Patient now experiences zero nightly sleep disturbances for first time; no adverse events reported.","First pediatric patient data from ongoing Investigator Pediatric Netherton Syndrome study."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-018234","json":"https://secwatch.observer/filing/0001104659-25-018234.json","markdown":"https://secwatch.observer/filing/0001104659-25-018234.md","text":"https://secwatch.observer/filing/0001104659-25-018234.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671502/000110465925018234/0001104659-25-018234-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671502/000110465925018234/tm257848d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T02:12:56.784118+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}